| NCT06717100 | Study to Determine Potential for Drug-drug Interactions When Co-administering Deupirfenidone (LYT-100) and Nintedanib | NOT_YET_RECRUITING | PHASE1 | 2024-12 | 2025-03 | 2025-02 |
| NCT05829226 | A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | RECRUITING | PHASE1 | 2022-12-12 | 2026-03 | 2025-12 |
| NCT05321420 | LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-07-22 | 2025-12-31 | 2024-10-15 |
| NCT05129865 | LYT-300 in Healthy Volunteers | COMPLETED | PHASE1, PHASE2 | 2021-12-07 | 2023-10-23 | 2023-10-18 |
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | COMPLETED | PHASE1, PHASE2 | 2020-12-15 | 2024-12-12 | 2024-12-12 |
| NCT04652518 | LYT-100 in Post-acute COVID-19 Respiratory Disease | TERMINATED | PHASE2 | 2020-12-11 | 2022-07-18 | 2022-06-28 |
| NCT04243837 | LYT-100 in Patients With BCRL | TERMINATED | PHASE2 | 2020-03-01 | 2022-09-09 | 2022-09-09 |